|
"AT-less" Type I Polyketide Synthases
|
5R01CA106150-04
|
$281,102
|
SHEN, BEN
|
UNIVERSITY OF WISCONSIN MADISON
|
|
1H NMR STUDIES OF NON-HODGKINS LYMPHOMA
|
5R01CA101700-04
|
$356,111
|
GLICKSON, JERRY
|
UNIVERSITY OF PENNSYLVANIA
|
|
2006 Glycolipid & Sphingolipid Gordon Conference
|
3R13CA119831-01S1
|
$15,000
|
MERRILL, ALFRED
|
GORDON RESEARCH CONFERENCES
|
|
4-Peroxycyclophosphamides for Brain Tumor Therapy
|
5R01CA100074-04
|
$217,702
|
STRUCK, ROBERT
|
CANCERMEDICA, LLC
|
|
A Biomarker Study of COX-2 Inhibitors in IPMN
|
5R03CA112629-02
|
$73,553
|
Schmidt, Christian
|
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
|
|
A Drosophila Model for MEN2 and Sporadic MTCs
|
5R01CA084309-07
|
$212,392
|
Cagan, Ross
|
WASHINGTON UNIVERSITY
|
|
A Mouse Model of TGFB1 and Tumor Immunosurveillance in Squamous Cell Cancer
|
5R01CA117957-02
|
$214,552
|
GLICK, ADAM
|
PENNSYLVANIA STATE UNIVERSITY-UNIV PARK
|
|
A new method for delivery of selinium for prevention of melanoma
|
5R03CA125854-02
|
$72,582
|
Cassidy, Pamela
|
UNIVERSITY OF UTAH
|
|
A Phase 0 Trial of Riluzole in Patients with Resectable Stage III or IV Melanoma
|
1R21CA126148-01
|
$204,380
|
GOYDOS, JAMES
|
UNIV OF MED/DENT NJ-R W JOHNSON MED SCH
|
|
A Phase 2 Trial of Dasatinib in Patients with NSCLC and Acquired Resistance to Er
|
1R21CA130343-01
|
$226,200
|
MILLER, VINCENT
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
A Phase I Study of Single Agent Flavopiridol in B-Cell *
|
5R21CA119595-02
|
$254,566
|
LIN, THOMAS
|
OHIO STATE UNIVERSITY
|
|
A PILOT INVESTIGATION OF ETHNIC DISPARITIES IN PATIENT-INITIATED PREMATURE TREATM
|
1R03CA128470-01
|
$72,000
|
Adams, Swann
|
UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
|
|
A Pilot Trial of Oral Melatonin Supplementation in Breast Cancer Survivors
|
5R03CA123597-02
|
$84,574
|
SCHERNHAMMER, EVA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
A POLYMERIC DRUG DELIVERY SYSTEM FOR CANCER THERAPY
|
5R01CA051578-15
|
$236,153
|
KOPECEK, JINDRICH
|
UNIVERSITY OF UTAH
|
|
A Transgenic Model for Prostate Tumor Immunity
|
5R01CA109339-04
|
$281,848
|
ADLER, ADAM
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
A Tumor Specific Therapy Approach for Small Cell Lung Cancer
|
5R21CA104297-02
|
$122,501
|
ZOU, YIYU
|
YESHIVA UNIVERSITY
|
|
A Two Hybrid System Based Yeasy Screen for Agents that Affect DNA Damage Checkpoi
|
1R43CA130224-01
|
$135,446
|
KUMAR, NALIN
|
UHV TECHNOLOGIES, INC.
|
|
A Yeast Model for Determining Tubulin-drug Interactions
|
5R01CA105305-04
|
$251,912
|
HIMES, RICHARD
|
UNIVERSITY OF KANSAS LAWRENCE
|
|
Aberrant Crypt Foci as a Biomarker for Chemoprevention
|
5R01CA113681-02
|
$462,908
|
SINICROPE, FRANK
|
MAYO CLINIC COLL OF MEDICINE, ROCHESTER
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
3P30CA016520-32S1
|
$215,193
|
THOMPSON, CRAIG
|
UNIVERSITY OF PENNSYLVANIA
|
|
Abramson Cancer Center of the U of P Core Support Grant
|
5P30CA016520-32
|
$7,282,327
|
Thompson, Craig
|
UNIVERSITY OF PENNSYLVANIA
|
|
ACSB Central Operations and Data Coodinating Center
|
3U01CA096230-05S1
|
$459,957
|
MCGRATH, MICHAEL
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
|
Addressing Fertility Issues with Female Cancer Patients
|
5R21CA114385-02
|
$175,312
|
ALLEN, SUSAN
|
BROWN UNIVERSITY
|
|
Adenosine Analogs: Therapeutics for Hematologic Cancers
|
3R01CA085915-07S1
|
$51,498
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
Adenosine Analogs: Therapeutics for Hematologic Cancers
|
5R01CA085915-07
|
$312,066
|
ROSEN, STEVEN
|
NORTHWESTERN UNIVERSITY
|
|
Adrenocortical Cancer (ACC) and Thyroid Carcinomas: Models of Cancers with Unique
|
Z01 BC 010626
|
$173,920
|
Fojo, Antonio
|
CCR (NCI)
|
|
Adult Leukemia Research Center
|
2P01CA018029-32
|
$5,086,500
|
APPELBAUM, FREDERICK
|
FRED HUTCHINSON CANCER RESEARCH CENTER
|
|
Advanced Anatomic and Functional Response Assessment in Lung Cancer
|
1R01CA125143-01A1
|
$354,322
|
SCHWARTZ, LAWRENCE
|
SLOAN-KETTERING INSTITUTE FOR CANCER RES
|
|
Aerosol Therapy for Lung Cancer
|
5R44CA096409-03
|
$371,115
|
Hansen, Brian
|
AEROPHASE, INC.
|
|
AIDS Malignancy Clinical Trials Corsortium
|
5U01CA121947-02
|
$5,296,416
|
MITSUYASU, RONALD
|
UNIVERSITY OF CALIFORNIA LOS ANGELES
|
|
Aldose Reductase-Like-1, a Novel Hepatocellular Carcinoma Drug Resistant Protein
|
1R21CA122327-01A1
|
$144,500
|
Cao, Deliang
|
SOUTHERN ILLINOIS UNIVERSITY SCH OF MED
|
|
Alkyltransferase Inhibitors for Cancer Chemotherapy
|
5R01CA071976-12
|
$250,931
|
PEGG, ANTHONY
|
PENNSYLVANIA STATE UNIV HERSHEY MED CTR
|
|
Allogeneic lymphocyte infusions to treat myeloid cancers
|
5R21CA121588-02
|
$282,657
|
FUCHS, EPHRAIM
|
JOHNS HOPKINS UNIVERSITY
|
|
Alpha Folate Receptor Mediated GARFTase Inhibitors as Selective Antitumor Agents
|
5R01CA125153-02
|
$253,704
|
GANGJEE, ALEEM
|
DUQUESNE UNIVERSITY
|
|
alphaBeta-crystallin: A Novel Biomarker in Breast Cancer
|
1R21CA125181-01
|
$181,200
|
CRYNS, VINCENT
|
NORTHWESTERN UNIVERSITY
|
|
Altered Arachidonic Acid Balance and Colon Cancer
|
5R01CA114635-02
|
$305,945
|
Rosenberg, Daniel
|
UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
|
|
American Academy of Cancer Education Annual Meetings - 2006, 2007, 2008
|
5R13CA126454-02
|
$19,420
|
VON GUNTEN, CHARLES
|
SAN DIEGO HOSPICE AND PALLIATIVE CARE
|
|
American College of Surgeons Oncology Group
|
3U10CA076001-11S1
|
$300,000
|
OTA, DAVID
|
DUKE UNIVERSITY
|
|
American College of Surgeons Oncology Group
|
5U10CA076001-11
|
$3,000,000
|
OTA, DAVID
|
DUKE UNIVERSITY
|
|
ANALOG STUDIES OF 4-HPR AND ITS GLUCURONIDE
|
5R01CA049837-14
|
$282,094
|
CURLEY, ROBERT
|
OHIO STATE UNIVERSITY
|
|
Analysis of AND-34 in human breast cancer
|
5R01CA114094-03
|
$229,749
|
LERNER, ADAM
|
BOSTON MEDICAL CENTER
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722001-001
|
$792,017
|
TURNER, GREGORY
|
MIDWEST RESEARCH INSTITUTE
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722002-001
|
$622,262
|
HINES, JOHN
|
RESEARCH TRIANGLE INSTITUTE
|
|
Analysis of Anti-Cancer Chemicals and Pharmaceutical Formulations
|
N02CM027134-007
|
$50,000
|
HE, JINGYI
|
S R I International
|
|
ANALYSIS OF ANTI-CANCER CHEMICALS AND PHARMACEUTICAL FORMULATIONS
|
N02CM722003-001
|
$826,749
|
WANG, JENNIE
|
SRI INTERNATIONAL
|
|
Analysis of Apigenin in Inhibiting Ovarian Tumorigenesis
|
5R03CA123675-02
|
$71,126
|
JIANG, BING-HUA
|
WEST VIRGINIA UNIVERSITY
|
|
Analysis of Circulating Tumor Cells in a Phase I/II Study for Breast Cancer
|
5R21CA121541-02
|
$307,278
|
SWABY, RAMONA
|
FOX CHASE CANCER CENTER
|
|
Analysis of Individual Trajectories of Oral Mucositis
|
5R01CA114263-02
|
$165,273
|
DUDLEY, WILLIAM
|
UNIVERSITY OF UTAH
|
|
Analysis of Patient Tumor Responses to Apo2L/TRAIL
|
5R01CA108888-02
|
$298,135
|
REPASKY, ELIZABETH
|
ROSWELL PARK CANCER INSTITUTE CORP
|
|
Anatomic and Biologic Staging of Breast Disease with MRI
|
5R01CA069587-10
|
$432,136
|
Hylton, Nola
|
UNIVERSITY OF CALIFORNIA SAN FRANCISCO
|
Relevant funding data is only available when one cancer type or one research topic is selected.
|